Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35


Overcoming Barriers to Development of Novel Therapies for Cardiovascular Disease: Insights From the Oncology Drug Development Experience.

Khakoo AY, Yurgin NR, Eisenberg PR, Fonarow GC.

JACC Basic Transl Sci. 2019 Apr 29;4(2):269-274. doi: 10.1016/j.jacbts.2019.01.011. eCollection 2019 Apr.


Utility of Glycosylated TIMP3 molecules: Inhibition of MMPs and TACE to improve cardiac function in rat myocardial infarct model.

Chintalgattu V, Greenberg J, Singh S, Chiueh V, Gilbert A, O'Neill JW, Smith S, Jackson S, Khakoo AY, Lee T.

Pharmacol Res Perspect. 2018 Nov 14;6(6):e00442. doi: 10.1002/prp2.442. eCollection 2018 Dec.


Delivery of a matrix metalloproteinase-responsive hydrogel releasing TIMP-3 after myocardial infarction: effects on left ventricular remodeling.

Purcell BP, Barlow SC, Perreault PE, Freeburg L, Doviak H, Jacobs J, Hoenes A, Zellars KN, Khakoo AY, Lee T, Burdick JA, Spinale FG.

Am J Physiol Heart Circ Physiol. 2018 Oct 1;315(4):H814-H825. doi: 10.1152/ajpheart.00076.2018. Epub 2018 Jul 6.


Intracoronary delivery of recombinant TIMP-3 after myocardial infarction: effects on myocardial remodeling and function.

Barlow SC, Doviak H, Jacobs J, Freeburg LA, Perreault PE, Zellars KN, Moreau K, Villacreses CF, Smith S, Khakoo AY, Lee T, Spinale FG.

Am J Physiol Heart Circ Physiol. 2017 Oct 1;313(4):H690-H699. doi: 10.1152/ajpheart.00114.2017. Epub 2017 Jul 28.


Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.

Povsic TJ, Scott R, Mahaffey KW, Blaustein R, Edelberg JM, Lefkowitz MP, Solomon SD, Fox JC, Healy KE, Khakoo AY, Losordo DW, Malik FI, Monia BP, Montgomery RL, Riesmeyer J, Schwartz GG, Zelenkofske SL, Wu JC, Wasserman SM, Roe MT.

Cardiovasc Drugs Ther. 2017 Aug;31(4):445-458. doi: 10.1007/s10557-017-6739-9. Review.


Cardiac myocyte p38α kinase regulates angiogenesis via myocyte-endothelial cell cross-talk during stress-induced remodeling in the heart.

Rose BA, Yokota T, Chintalgattu V, Ren S, Iruela-Arispe L, Khakoo AY, Minamisawa S, Wang Y.

J Biol Chem. 2017 Aug 4;292(31):12787-12800. doi: 10.1074/jbc.M117.784553. Epub 2017 Jun 21.


Hypertension and Circulating Cytokines and Angiogenic Factors in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma Treated With Sunitinib: Results From a Phase II Trial.

Bilen MA, Zurita AJ, Ilias-Khan NA, Chen HC, Wang X, Kearney AY, Hodges S, Jonasch E, Huang S, Khakoo AY, Tannir NM.

Oncologist. 2015 Oct;20(10):1140-8. doi: 10.1634/theoncologist.2015-0143. Epub 2015 Aug 25.


Coronary microvascular pericytes are the cellular target of sunitinib malate-induced cardiotoxicity.

Chintalgattu V, Rees ML, Culver JC, Goel A, Jiffar T, Zhang J, Dunner K Jr, Pati S, Bankson JA, Pasqualini R, Arap W, Bryan NS, Taegtmeyer H, Langley RR, Yao H, Kupferman ME, Entman ML, Dickinson ME, Khakoo AY.

Sci Transl Med. 2013 May 29;5(187):187ra69. doi: 10.1126/scitranslmed.3005066.


Smooth muscle hyperplasia due to loss of smooth muscle α-actin is driven by activation of focal adhesion kinase, altered p53 localization and increased levels of platelet-derived growth factor receptor-β.

Papke CL, Cao J, Kwartler CS, Villamizar C, Byanova KL, Lim SM, Sreenivasappa H, Fischer G, Pham J, Rees M, Wang M, Chaponnier C, Gabbiani G, Khakoo AY, Chandra J, Trache A, Zimmer W, Milewicz DM.

Hum Mol Genet. 2013 Aug 1;22(15):3123-37. doi: 10.1093/hmg/ddt167. Epub 2013 Apr 15.


Metastatic melanoma presenting as polymorphic ventricular tachycardia.

Sharma J, Brunson JM, Memon N, Khakoo AY.

Tex Heart Inst J. 2012;39(6):890-3.


Mesenchymal stem cells regulate blood-brain barrier integrity through TIMP3 release after traumatic brain injury.

Menge T, Zhao Y, Zhao J, Wataha K, Gerber M, Zhang J, Letourneau P, Redell J, Shen L, Wang J, Peng Z, Xue H, Kozar R, Cox CS Jr, Khakoo AY, Holcomb JB, Dash PK, Pati S.

Sci Transl Med. 2012 Nov 21;4(161):161ra150. doi: 10.1126/scitranslmed.3004660.


Reducing the toxicity of cancer therapy: recognizing needs, taking action.

Cleeland CS, Allen JD, Roberts SA, Brell JM, Giralt SA, Khakoo AY, Kirch RA, Kwitkowski VE, Liao Z, Skillings J.

Nat Rev Clin Oncol. 2012 Jul 3;9(8):471-8. doi: 10.1038/nrclinonc.2012.99. Review.


Human mesenchymal stem cells inhibit endothelial proliferation and angiogenesis via cell-cell contact through modulation of the VE-Cadherin/β-catenin signaling pathway.

Menge T, Gerber M, Wataha K, Reid W, Guha S, Cox CS Jr, Dash P, Reitz MS Jr, Khakoo AY, Pati S.

Stem Cells Dev. 2013 Jan 1;22(1):148-57. doi: 10.1089/scd.2012.0165. Epub 2012 Jun 26.


Molecular mechanisms of hypertension and heart failure due to antiangiogenic cancer therapies.

Rees ML, Khakoo AY.

Heart Fail Clin. 2011 Jul;7(3):299-311. doi: 10.1016/j.hfc.2011.03.004. Review.


Cardiotoxicity due to cancer therapy.

Khakoo AY, Liu PP, Force T, Lopez-Berestein G, Jones LW, Schneider J, Hill J.

Tex Heart Inst J. 2011;38(3):253-6. Review.


MicroRNA-9 is an activation-induced regulator of PDGFR-beta expression in cardiomyocytes.

Zhang J, Chintalgattu V, Shih T, Ai D, Xia Y, Khakoo AY.

J Mol Cell Cardiol. 2011 Sep;51(3):337-46. doi: 10.1016/j.yjmcc.2011.05.019. Epub 2011 Jun 17.


Coronary flow reserve in mice: effects of age, coronary disease, and vascular loading.

Hartley CJ, Reddy AK, Michael LH, Entman ML, Chintalagattu V, Khakoo AY, Taffet GE.

Conf Proc IEEE Eng Med Biol Soc. 2010;2010:3780-3. doi: 10.1109/IEMBS.2010.5627571.


Mesenchymal stem cells stimulate protective genetic reprogramming of injured cardiac ventricular myocytes.

Rogers TB, Pati S, Gaa S, Riley D, Khakoo AY, Patel S, Wardlow RD 2nd, Frederick CA, Hall G, He LP, Lederer WJ.

J Mol Cell Cardiol. 2011 Feb;50(2):346-56. doi: 10.1016/j.yjmcc.2010.09.001. Epub 2010 Sep 15.


Human mesenchymal stem cells inhibit vascular permeability by modulating vascular endothelial cadherin/β-catenin signaling.

Pati S, Khakoo AY, Zhao J, Jimenez F, Gerber MH, Harting M, Redell JB, Grill R, Matsuo Y, Guha S, Cox CS, Reitz MS, Holcomb JB, Dash PK.

Stem Cells Dev. 2011 Jan;20(1):89-101. doi: 10.1089/scd.2010.0013. Epub 2010 Oct 18.


Review: cardiovascular toxicities due to molecularly targeted cancer therapeutics.

Chintalgattu V, Khakoo AY.

Clin Adv Hematol Oncol. 2010 Feb;8(2):133-5. Review. No abstract available.


Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress.

Chintalgattu V, Ai D, Langley RR, Zhang J, Bankson JA, Shih TL, Reddy AK, Coombes KR, Daher IN, Pati S, Patel SS, Pocius JS, Taffet GE, Buja LM, Entman ML, Khakoo AY.

J Clin Invest. 2010 Feb;120(2):472-84. doi: 10.1172/JCI39434. Epub 2010 Jan 11.


Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate.

Trent JC, Patel SS, Zhang J, Araujo DM, Plana JC, Lenihan DJ, Fan D, Patel SR, Benjamin RS, Khakoo AY.

Cancer. 2010 Jan 1;116(1):184-92. doi: 10.1002/cncr.24683.


Cardiovascular effects of tyrosine kinase inhibitors used for gastrointestinal stromal tumors.

Chintalgattu V, Patel SS, Khakoo AY.

Hematol Oncol Clin North Am. 2009 Feb;23(1):97-107, viii-ix. doi: 10.1016/j.hoc.2008.11.004. Review.


Does the renin-angiotensin system participate in regulation of human vasculogenesis and angiogenesis?

Khakoo AY, Sidman RL, Pasqualini R, Arap W.

Cancer Res. 2008 Nov 15;68(22):9112-5. doi: 10.1158/0008-5472.CAN-08-0851. Review.


Therapy insight: Management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy.

Khakoo AY, Yeh ET.

Nat Clin Pract Oncol. 2008 Nov;5(11):655-67. doi: 10.1038/ncponc1225. Epub 2008 Sep 16. Review.


Sunitinib-related cardiotoxicity: an interdisciplinary issue.

Ewer MS, Lenihan DJ, Khakoo AY.

Nat Clin Pract Cardiovasc Med. 2008 Jul;5(7):364-5. doi: 10.1038/ncpcardio1222. Epub 2008 May 20. No abstract available.


Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor.

Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, Trent J 2nd, Champion JC, Durand JB, Lenihan DJ.

Cancer. 2008 Jun;112(11):2500-8. doi: 10.1002/cncr.23460.


Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma.

Khakoo AY, Pati S, Anderson SA, Reid W, Elshal MF, Rovira II, Nguyen AT, Malide D, Combs CA, Hall G, Zhang J, Raffeld M, Rogers TB, Stetler-Stevenson W, Frank JA, Reitz M, Finkel T.

J Exp Med. 2006 May 15;203(5):1235-47. Epub 2006 Apr 24.


Reversible cardiomyopathy caused by administration of interferon alpha.

Khakoo AY, Halushka MK, Rame JE, Rodriguez ER, Kasper EK, Judge DP.

Nat Clin Pract Cardiovasc Med. 2005 Jan;2(1):53-7.


Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells.

Arbab AS, Yocum GT, Rad AM, Khakoo AY, Fellowes V, Read EJ, Frank JA.

NMR Biomed. 2005 Dec;18(8):553-9.


Endothelial progenitor cells.

Khakoo AY, Finkel T.

Annu Rev Med. 2005;56:79-101. Review.


Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI.

Arbab AS, Yocum GT, Kalish H, Jordan EK, Anderson SA, Khakoo AY, Read EJ, Frank JA.

Blood. 2004 Aug 15;104(4):1217-23. Epub 2004 Apr 20.


Underuse of coronary revascularization procedures.

Khakoo AY, Rastegar DA.

N Engl J Med. 2001 Jul 26;345(4):295; author reply 295-6. No abstract available.


An aggressive form of polyarticular arthritis in a man with CD154 mutation (X-linked hyper-IgM syndrome).

Webster EA, Khakoo AY, Mackus WJ, Karpusas M, Thomas DW, Davidson A, Christian CL, Lederman S.

Arthritis Rheum. 1999 Jun;42(6):1291-6.

Supplemental Content

Loading ...
Support Center